Whether you opt for in-clinic care, mobile services, injections or occasional medical infusions, informed decisions start with transparency
Our team is happy to provide personalized recommendations to maximize your results
Long-Acting Amylin Agonist GUB014295 Gubra A/S (Hrsholm, Denmark), a biotech company specialized in pre-clinical contract research, initiated a phase 1 clinical trial (NCT06144684) to investigate the safety, tolerability and pharmacological properties of GUB014295 (GUBamy), a long-acting OW SC amylin agonist, in healthy volunteers [117]
PGI2 probably increases Th2 cell function by IP (PGI2 receptor) to reduce the production of IL-1, IL-6, and monocyte chemoattractant protein (MCP)-1 (162)
Group members also recommended refraining from including the Emergency Care Access & Timeliness eCQM in Overall Hospital Quality Star Ratings (Star Ratings) due to the possible duplication of data with existing measures
Determine if your current dose is providing a therapeutic benefit
